Search jobs 29-Apr-2021
SEATTLE, April 29, 2021, (PHARMIWEB) Overview:
Glaucoma is a category of diseases marked by optic nerve injury, visual field loss, and secondary retinal ganglion cell damage, both of which can result in death.
Glaucoma is the world’s second leading cause of blindness and the leading cause of permanent blindness globally, according to the International Agency for the Prevention of Blindness. Primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG) are the two most common forms of glaucoma. The chance of developing glaucoma rises with age, increased intraocular pressure, a favorable family history of glaucoma, and ethnicity.
Subversive Acquisition LP Closes Transaction With InterCure, Israel’s Leading and Fastest-Growing Cannabis Company
InterCure is the Most Well-Capitalized Cannabis Company in Israel and is Positioned to Consolidate the Israeli Market and Further Expand Across Europe
Combined Company led by Chairman and Former Prime Minister of Israel Ehud Barak and CEO Alex Rabinovitch
InterCure has Doubled Revenues Sequentially in Four of the Last Five Quarters; Growth Plans Include Tripling Retail Footprint by 2022
Common Shares of InterCure now Trade on the TSX Under the Symbol “INCR.U” and the TASE Under the Symbol “INCR”
Listing of InterCure’s Shares on NASDAQ Expected in Q2 2021 and Will Trade Under the Symbol “INCR”
Subversive Acquisition LP Provides Update on Qualifying Transaction With InterCure, Israel’s Leading and Fastest-Growing Cannabis Company
Subversive Acquisition LP Has Met All Conditions of Closing and Expects to Close on or Before Friday April 23, 2021
SPAC Restricted Voting Units Currently Trade on the TSX Under the Symbol “SVX.U” and the OTCQX Under the Symbol “SBVRF”
On Closing Common Shares of InterCure will Trade on the TSX Under the Symbol “INCR.U” and the TASE Under the Symbol “INCR”
Listing of InterCure’s Shares on NASDAQ Expected in Q2 2021 and Trade Under the Symbol “INCR”
NEW YORK and TORONTO and HERZLIYA, Israel, April 21, 2021 (GLOBE NEWSWIRE) Subversive Acquisition LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) a special purpose acquisition company (SPAC), today announced it has met all conditions of closing, with the exception for the closing condition that will be met upon InterCure’s shares trading on the TSX, for its qualify
Subversive Acquisition LP Provides Update on Qualifying Transaction
Nachrichtenquelle: globenewswire | 11.04.2021, 03:58 | 57
SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“
SVX”) announced today that closing of its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company, is expected to occur as soon as practicable after the outstanding conditions to closing are met, which SVX expects to be on or before April 20, 2021.
About SVX Subversive Acquisition LP is a limited partnership established under the Limited Partnerships Act (Ontario) formed for the purpose of effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, equity exchange, asset acquisition, equity purchase, reorganization, or any other similar business combination involvi
Subversive Acquisition LP Announces Extension of Permitted Timeline for Completion of Its Qualifying Transaction
TORONTO, April 08, 2021 (GLOBE NEWSWIRE)
SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“
SVX”) announced today that the date by which SVX has to consummate its qualifying transaction is extended to August 31, 2021 (the “
Extension”).
On January 26, 2021, SVX announced its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company (the “
Business Combination”). Canndoc, a wholly owned subsidiary of InterCure Ltd., is Israel’s largest licensed cannabis producer.
On April 6, 2021, unitholders approved the Business Combination, with over 89.36% of the votes cast in favour of the plan of arrangement (the “